Fig. 2

SLC1A1 enhanced glutamine uptake and was highly expressed in patients with NKTCL.

(a) LASSO regression analysis in 10-fold cross-validation was performed with selected metabolites (glutamate, glutamine, and aspartate). Two dotted vertical lines marked the lambda at minimum and 1-s.e. mean-squared error, respectively.

(b) LASSO coefficient profiles of 26 SLC-family genes. A vertical line indicated the value of lambda at minimum mean-squared error.

(c) Tumor EAAT3 expression detected by immunohistochemistry.

(d) Quantification of targeted amino acids (arranged by P values from left to right) in serum samples of NKTCL patients (n=88) according to tumor EAAT3 expression.

(e) Quantification of targeted amino acids (arranged by P values from left to right) in cytoplasm samples of NK-92 cells transfected with SLC1A1 vector or control vector.

(f) Tumor EAAT3 expression correlated with its mRNA levels in NKTCL patients (n=100).

(g) Correlation of tumor SLC1A1 mRNA expression with serum glutamine levels in NKTCL patients (n=102).

Assays in (e) were set up in 6 replicated. Data in (d), (e) and (f) were represented as mean ±SD. P values in (c) were calculated by Pearson's chi-square test. P values in (d), (e) and (f) were calculated with unpaired t-test. P value in (g) was calculated by Pearson correlation test.